IGHG3 and COVID-19: The univariate analysis confirmed no differences in SARS-CoV-2-specific IgG1, IgG3 and IgM titers to the WT- and beta-S between beta VOC breakthrough cases and individuals who did not develop COVID-19 (Fig. 2b,c).